Oceania · General news · The Australian
Neurizon advances Regimen I into treatment extension alongside $3.7m R&D drawdown
Detailed summary
The first participant in Regimen I of Neurizon Therapeutics’ Phase 2/3 ALS Platform Trial has completed the 36-week randomised controlled trial (RCT) phase and transitioned into…
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.theaustralian.com.au)


